Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOBID vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity,Off-label: Adjuvant in treatment of obstructive sleep apnea
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Exhibits saturable (nonlinear) pharmacokinetics at high doses.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
40-60% (primarily to albumin). Decreased binding in neonates, hepatic disease, and uremia.
Approximately 70% bound to plasma proteins, primarily albumin.
0.45 L/kg (range: 0.3-0.7 L/kg). Higher in neonates (0.7-0.9 L/kg). Represents distribution throughout total body water.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 96-100% (immediate release); Sustained release (THEOBID): ~100% (bioequivalent to immediate release at steady state); IV: 100%; Rectal: ~80-100%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No specific GFR-based dose adjustment for theophylline. However, accumulation may occur in severe renal impairment; monitor serum levels and adjust dose to achieve therapeutic concentrations (10-20 mcg/m L).
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B or C: Reduce dose by 75% or use alternative. Monitor serum concentrations closely.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
For asthma: Oral immediate-release: 5 mg/kg/day divided q6-8h. Extended-release: 10-20 mg/kg/day divided q12h (max 600 mg/day). Target serum concentration 5-15 mcg/m L. Dosing based on age and weight, titrate slowly.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Elderly patients (>60 years) often have reduced clearance. Start with 300 mg/day orally extended-release, titrate slowly to lowest effective dose. Monitor serum concentrations closely to avoid toxicity (target 5-15 mcg/m L).
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Risk of serious cardiovascular toxicity (arrhythmias, seizures, death) especially at serum levels >20 mcg/m L,Cautious use in patients with peptic ulcer, seizure disorders, cardiac disease, hepatic impairment,Monitor serum theophylline levels to avoid toxicity,Reduce dose in smokers and with drugs that induce CYP1A2 (e.g., phenytoin, rifampin),Avoid in patients with active peptic ulcer or uncontrolled seizure disorders
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component of the formulation.
High-fat meals can increase absorption of sustained-release formulations. Charcoal-broiled foods and a high-protein, low-carbohydrate diet can increase theophylline clearance. Avoid concurrent ingestion of caffeine-containing foods/beverages.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No known structural effects; fetal tachycardia and irritability may occur due to maternal toxicity. Neonatal withdrawal (jitteriness, vomiting) reported with third-trimester use.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels may reach therapeutic concentrations, especially in preterm neonates. Risk of irritability, jitteriness, and feeding problems. Benefit of breastfeeding should be weighed against potential adverse effects; monitor infant for theophylline toxicity.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy increases theophylline clearance due to elevated cardiac output and increased hepatic metabolism, particularly in the second and third trimesters. Dose may need to be increased by 30-50% to maintain therapeutic levels. Postpartum, clearance decreases; dose should be reduced to prepregnancy levels within 2 weeks to avoid toxicity. Monitor serum levels and adjust accordingly.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline levels must be monitored; narrow therapeutic index (5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Many drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) increase levels. Smoking induces metabolism, requiring higher doses.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not change dose without consulting doctor.,Do not crush or chew sustained-release capsules.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms like nausea, vomiting, palpitations, insomnia, or seizures.,Notify doctor if you start or stop smoking, or if you are prescribed new medications.,Keep regular appointments for blood level monitoring.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOBID vs AEROLATE JR, answered by our medical review team.
THEOBID is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOBID and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOBID is: Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOBID and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOBID is classified as Category C. Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No . AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.